Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Total Current Liabilities (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Total Current Liabilities for 16 consecutive years, with $37.4 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 0.9% to $37.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.4 million through Dec 2025, up 0.9% year-over-year, with the annual reading at $37.4 million for FY2025, 0.9% up from the prior year.
  • Total Current Liabilities hit $37.4 million in Q4 2025 for Ligand Pharmaceuticals, up from $30.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $167.9 million in Q2 2022 to a low of $15.7 million in Q3 2023.
  • Historically, Total Current Liabilities has averaged $56.1 million across 5 years, with a median of $39.6 million in 2021.
  • Biggest five-year swings in Total Current Liabilities: surged 368.76% in 2021 and later tumbled 88.37% in 2023.
  • Year by year, Total Current Liabilities stood at $41.7 million in 2021, then surged by 137.15% to $98.8 million in 2022, then crashed by 83.02% to $16.8 million in 2023, then surged by 121.14% to $37.1 million in 2024, then rose by 0.9% to $37.4 million in 2025.
  • Business Quant data shows Total Current Liabilities for LGNDZ at $37.4 million in Q4 2025, $30.5 million in Q3 2025, and $64.7 million in Q2 2025.